1 Small-Cap Stock with Promising Prospects and 2 That Underwhelm
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) investors concerning...
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended...
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Myriad Genetics, Inc. (“Myriad”...
Myriad Genetics showed investors an adjusted EBITDA target of $37 million to $49 million for 2026. Months later, the Company suspended adjusted EBITDA guidance entirely -- leaving MYGN shareholders to...
On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended...
Why Myriad Genetics (MYGN) Shares Are Falling Today
Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%